drugset
Drugs / SAR113945
last change Feb 2013 re-read 3 minutes ago

SAR113945

targets IKBKB via inhibition

Developed for
osteoarthritis, knee · osteoarthritis
Investigated by
Sanofi

Trials 4

today NCT01598415 · Ph 2 NCT01511549 · Ph 1 NCT01463488 · Ph 1 NCT01113333 · Ph 1
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT01511549 Jan → Sep 2012 osteoarthritis, knee Sanofi Completed No outcome recorded
Phase 1 NCT01463488 Nov 2011 → Aug 2012 osteoarthritis, knee Sanofi Completed No outcome recorded
Phase 1 NCT01113333 Apr 2010 → Feb 2011 osteoarthritis Sanofi Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01598415 Apr 2012 → Feb 2013 osteoarthritis, knee Sanofi Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as SAR113945 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01598415 ↗
3

NCT01511549 ↗

NCT01463488 ↗

NCT01113333 ↗
Action Inhibit “Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor” CHEMBL3544945 ↗
1

“IKK Inhibitor” NCT01113333 ↗
Route Other “Route of administration: intra-articular” NCT01113333 ↗
Target IKBKB “Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor” CHEMBL3544945 ↗